… Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous … in
the setting of persistently positive levels of antiphospholipid antibodies measured on 2 different …

… whereby pathogenic antiphospholipid antibodies (… therapeutic targets that are currently
being explored for APS in order to address the unmet needs of better, safer and ideally targeted …

Antiphospholipid (aPL) antibodies (Abs) are associated with thrombosis and pregnancy loss
in antiphospholipid syndrome … triggered by aPL Abs on target cells in coagulation pathways …

… This review summarizes the available data on potential therapeutic targets which may
address the unmet needs of a more effective and safe therapy for patients with APS. …

… recent clinical studies with other targeted therapies discussed below have been … targeted
therapies to background immunosuppression with MMF may become an effective therapeutic …

… trial of novel therapies targeting those mechanisms. Following … evidence for these potential,
targeted APS treatments, eg, … it is often considered a therapeutic target in refractory CAPS …

… therapeutic strategies are being tested, and some have been found effective for the primary
and secondary thromboprophylaxis in antiphospholipid syndrome. … at a target INR of 2.0–3.0 …

… Some study groups proposed new targeted therapeutic strategies some of which have
shown promising results in preclinical studies. These include Rituximab, complement inhibition, …

… All of these may serve as future therapeutic targets. Neutrophils produce neutrophil …
NETosis can be targeted not only with several experimental therapeutics, such as DNase, …

… that could yield to new potential treatment targets, better identification of criteria and non-criteria
clinical phenotypes, antiphospholipid antibody profiles and their associations with …